Ultima-AOD9604 5mg

MANUFACTURER
Ultima Pharmaceuticals - USA
WAREHOUSE
USA Warehouse 5
SUBSTANCE
Anti-Obesity Drug - AOD 9604

For added security, our products are shipped without branding.

AOD 9604 is a groundbreaking modified variant of Growth Hormone, crafted from a 191 amino acid peptide. Specifically, it consists of the last 15 amino acids (positions 176-191) from the Growth Hormone structure, synthesized into a unique peptide known as GH Frag 176-191, or AOD 9604. Recognized as one of the most effective peptides for weight loss, AOD 9604 not only promotes fat loss but also enhances metabolism and offers a myriad of additional benefits.

Gland Stimulated: Pituitary Gland

• Effectively reduces body fat
• Targets the release of fat from primarily obese fat cells, sparing lean tissue
• Mimics the natural fat metabolism regulation of growth hormone
• Maintains stable blood sugar levels without impacting growth
• Stimulates lipolysis, promoting fat breakdown
• Inhibits lipogenesis, preventing the conversion of non-fatty foods into body fat
• Demonstrates promising properties for cartilage repair and regeneration, especially in conjunction with peptide BPC 157.

Mechanism of Action:

AOD-9604, also known as Tyr-hGH Frag 176-191, is renowned for its remarkable fat-burning ability without stimulating appetite. It operates independently of hGH receptors and does not affect blood sugar or tissue growth (Heffernan 2001, Ng 2000). This innovative peptide activates fat oxidation, facilitating the release of fat from obese cells while curbing new fat accumulation. Notably, AOD-9604 excels at targeting abdominal fat reduction.

When considering fat loss, it's essential to note that CJC-1295, another powerful fat loss peptide, increases overall GH levels, counteracting age-related declines that lead to fat gain. For optimal fat loss, it?s advisable to avoid GHRP products (like GHRP-6 or GHRP-2), as they may increase appetite and cortisol levels. AOD-9604, on the other hand, does not induce hunger or cortisol spikes.

AOD 9604 Research:

Originally developed in the 1990s by Professor Frank Ng at Monash University in Australia, AOD-9604 (Advanced Obesity Drug) was designed to harness the fat-burning benefits of human growth hormone (HGH) without encouraging muscle growth. Recent studies have unveiled that AOD 9604 possesses various regenerative qualities linked to growth hormone, with ongoing clinical trials exploring its potential in treating osteoarthritis, hypercholesterolemia, and aiding bone and cartilage repair.

Results from oral glucose tolerance tests indicate that, unlike HGH, AOD 9604 does not negatively impact carbohydrate metabolism. Moreover, no anti-AOD 9604 antibodies were detected in patients during antibody assays, and no significant withdrawal symptoms or adverse effects were reported in any studies.

Conclusion:

AOD 9604 showcases an impressive safety and tolerability profile, akin to that of a placebo, without the adverse effects commonly associated with full-length hGH treatments. With an excellent safety record, AOD 9604 has recently achieved Human GRAS status in the USA.